Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula

Interview: Jason Gardner On Goal To Develop A New Targeted Medicine Paradigm

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

Jason Gardner is just a month into his role as CEO of Ampersand Biomedicines, one of the latest companies to emerge from Flagship Pioneering, but is nevertheless confident it can deliver a “new paradigm in biologics discovery and development.”

Flagship set up Ampersand Biomedicines in 2021, but only revealed the company’s existence and mission in March this year: to develop a suite of “smarter medicines” that act specifically at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

30 May 2025

• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback